Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Email: noa.krawczyk@nyulangone.org
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public HealthBA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery. Projects
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications
Recent
Krawczyk N, Lim S, Cherian T, Goldfeld KS, Katyal M, Rivera BD, McDonald R, Khan M, Wiewel E, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Kutscher E, Khatri UG, Rosner Z, Vail WL, MacDonald R, Lee JD (2024).
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study
Drug and Alcohol Dependence, 261, 111377. doi: 10.1016/j.drugalcdep.2024.111377.
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study
Drug and Alcohol Dependence, 261, 111377. doi: 10.1016/j.drugalcdep.2024.111377.
Englander H, Chappuy M, Krawczyk N, Bratberg J, Potee R, Jauffret-Roustide M, Rolland B (2024).
Comparing methadone policy and practice in France and the US: Implications for US policy reform
International Journal of Drug Policy, 129, 104487. doi: 10.1016/j.drugpo.2024.104487.
Comparing methadone policy and practice in France and the US: Implications for US policy reform
International Journal of Drug Policy, 129, 104487. doi: 10.1016/j.drugpo.2024.104487.
Burke KN, Krawczyk N, Li Y, Byrne L, Desai IK, Bandara S, Feder KA (2024).
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership
Journal of Substance Use and Addiction Treatment, 162, 209351. doi: 10.1016/j.josat.2024.209351.
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership
Journal of Substance Use and Addiction Treatment, 162, 209351. doi: 10.1016/j.josat.2024.209351.
Cherian T, Lim S, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD (2024).
Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Drug and Alcohol Dependence, 259, 111274. doi: 10.1016/j.drugalcdep.2024.111274.
Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
Drug and Alcohol Dependence, 259, 111274. doi: 10.1016/j.drugalcdep.2024.111274.
Franz B, Cronin CE, Lindenfeld Z, Pagan JA, Lai AY, Krawczyk N, Rivera BD, Chang JE (2024).
Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services
Journal of Substance Use and Addiction Treatment, 160, 209280. doi: 10.1016/j.josat.2023.209280. PMCID: PMC11060933.
Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services
Journal of Substance Use and Addiction Treatment, 160, 209280. doi: 10.1016/j.josat.2023.209280. PMCID: PMC11060933.
Notable
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.
Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.
Dr. Krawczyk's MyBibliography Profile
Selected Press